Synthesis of Biologically Active Vitamin K-Dependent Coagulation Factors

  • Barbara C. Furie
  • Bruce Furie


Several of the vitamin K-dependent proteins of blood coagulation have elicited interest as potential therapeutic agents for disorders of hemostasis or thrombosis. In particular, there has been interest in producing recombinant factor IX for treatment of hemophilia B, factor VII for treatment of hemophilia A patients with inhibitors and recombinant protein C for treatment of thrombotic disorders. Since these proteins undergo a unique posttranslational modification, the vitamin K-dependent carboxylation of specific glutamic acid residues in their amino termini to γ-carboxyglutamic acid, their expression in recombinant systems has been more difficult than that of proteins that undergo less extensive processing. A great deal of experience has been accrued on optimal expression systems and methods of growth for the vitamin K-dependent proteins. While some of these proteins are now produced on a scale that makes consideration of therapeutic use feasible, obstacles still remain to the practical production of others. For example, it remains difficult to produce fully carboxylated factor IX at high levels of expression in recombinant systems. Some of these obstacles may be surmountable with an increased understanding of the basic biological processes involved in the synthesis of the vitamin K-dependent proteins. Considerable interest has been focused on two fundamental problems: what are the factors that control the efficient γ-carboxylation of a vitamin K-dependent protein and, what effects efficient cleavage of the propeptide of a vitamin K-dependent protein? Our current understanding of the former, the process of γ-carboxylation, is the subject of this review.


Carboxyglutamic Acid Concensus Sequence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Soute BAM, Vermeer C, DeMetz M, Hemker HC, Lijnen HR: In vitro prothrombin synthesis from a purified precursor protein. Biochim. Biophys. Acta 67: 101–107, 1981CrossRefGoogle Scholar
  2. 2.
    Esmon CT, Grant GA, Suttie JW: Purification of an apparent rat liver prothrombin precursor: characterization and comparison to normal rat prothrombin. Biochemistry 14: 1595–1600, 1975PubMedCrossRefGoogle Scholar
  3. 3.
    Degen SJ, MacGillivray RT, Davie EW: Characterization of the cDNA and gene coding for human prothrombin. Biochemistry 22: 2087–2097, 1983PubMedCrossRefGoogle Scholar
  4. 4.
    Jorgensen MJ, Cantor AB, Furie BC and Furie B: Expression of completely γ-carboxylated recombinant human prothrombin. J. Biol. Chem. 262: 6729–6734, 1987PubMedGoogle Scholar
  5. 5.
    Fung MR, Hay CW, MacGillivray, RTA: Characterization of an almost full-length cDNA coding for human factor X. Proc. Natl. Acad. Sci. USA 82: 3591–3595, 1985PubMedCrossRefGoogle Scholar
  6. 6.
    Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie, EW: Characterization of a cDNA coding for human factor X. Proc. Natl. Acad. Sci. USA: 81: 3699–3702Google Scholar
  7. 7.
    Hagen FS, Gray CL, O’Hara P, Grant FJ, Saari GC, Woodbury RG, Hart CE, Insley M, Kisiel W, Kurachi K, Davie EW: Characterization of the cDNA coding for human factor VII. Proc. Natl. Acad. Sci. USA: 83: 2412–2416, 1986PubMedCrossRefGoogle Scholar
  8. 8.
    Kurachi K, Davie EW: Isolation and characterization of a cDNA coding for human factor IX. Proc. Natl., Acad. Sci. USA, 79: 6461–6464, 1982.CrossRefGoogle Scholar
  9. 9.
    Choo KH, Gould KG, Rees DJG, Brownlee GG: Molecular cloning of the gene for human anti-haemophilic Factor IX. Nature 299: 178–180, 1982PubMedCrossRefGoogle Scholar
  10. 10.
    Foster D, Davie, EW: Characterization of cDNA coding for human protein C. Proc. Natl. Acad. Sci. USA 81: 4766–4770, 1984PubMedCrossRefGoogle Scholar
  11. 11.
    Long Gl, Belagaje RM, MacGillivray, RTA: Cloning and sequencing of liver cDNA coding for bovine protein C. Proc. Natl. Acad. Sci. USA 81: 5653–5656, 1984PubMedCrossRefGoogle Scholar
  12. 12.
    Hoskins J, Norma DK, Beckmann RJ, Long GL: Cloning and characterization of human liver cDNA encoding a protein S precursor. Proc. Natl. Acad. Sci. USA 84: 3536, 1987CrossRefGoogle Scholar
  13. 13.
    Lundwall A, Dackowski W, Cohen E, Shaffer M, Mahr A, Dahlback B, Stenflo J, Wydro R: Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. Proc. Natl. Acad. Sci. USA 83: 6716–6720, 1986PubMedCrossRefGoogle Scholar
  14. 14.
    Price PA, Poser JW, Raman N: Primary structure of the gamma-carboxyglutamic acid-containing protein from bovine bone. Proc. Natl. Acad. Sci. USA 84: 8335–8339, 1987PubMedCrossRefGoogle Scholar
  15. 15.
    Celeste AJ, Buecker JL, Kriz R, Wang EA, Wozney JM: Isolation of the human gene for bone Gla protein utilizing mouse and rat cDNA clones. EMBO J 5: 1885–1890, 1986PubMedGoogle Scholar
  16. 16.
    Price PA, Williamson MK: Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J. Biol. Chem. 260: 14971–14975, 1985PubMedGoogle Scholar
  17. 17.
    Price PA, Fraser JD, Metz-Vira G: Molecular cloning of matrix Gla protein: Implications for substrate recognition by the vitamin K-dependent γ-carboxylase. Proc. Natl. Acad. Sci. USA 84: 8335–8339, 1987PubMedCrossRefGoogle Scholar
  18. 18.
    Pan LC, Price PA: The propeptide of rat bone γ-carboxyglutamic acid protein shares homology with other vitamin K-dependent protein precursors. Proc. Nat. Acad. Sci. USA 82: 6109–6113, 1985PubMedCrossRefGoogle Scholar
  19. 19.
    Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie, B. Recognition site directing vitamin K-dependent γ-carboxylation resides on the propeptide of Factor IX. Cell 48: 185–191, 1987PubMedCrossRefGoogle Scholar
  20. 20.
    Diuguid DL, Rabiet M-J, Furie BC, Liebman HA, Furie B: Molecular basis of hemophilia B: A defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proc. Natl. Acad. Sci. USA 83: 5803–5807Google Scholar
  21. 21.
    Ware J, Diuguid DL, Liebman HA, Rabiet, M-J, Kasper CK, Furie BC, Furie, B, Stafford, DW: Factor IX San Dimas: Substitution of glutamine for arginine-4 in the propeptide leads to incomplete γ-carboxylation and altered phospholipid binding properties. J. Biol. Chem. 264: 11401–11406, 1989PubMedGoogle Scholar
  22. 22.
    Foster DC, Rudinski MS, Schach BG, Berkner KL, Kumar AA, Hagen FS, Sprecher CA, Insley MY, Davie, EW: Propeptide of human protein C is necessary for γ-carboxylation. Biochemistry 26: 7003–7011Google Scholar
  23. 23.
    Huber P, Schmitz T, Furie BC, Furie B: Identification of amino acids in the γ-carboxylation recognition site on the proepetide of prothrombin. J. Biol. Chem. 265: 12467–12473, 1990PubMedGoogle Scholar
  24. 24.
    Soute BAM, Ulrich MMW, Vermeer C: Vitamin K-dependent carboxylase. Increased efficiency of the reaction. Thromb. Haemost. 57: 5827–5830, 1987Google Scholar
  25. 25.
    Decottignies-Le Marechal P, Rikong-Adie H, Azerad R: Biochem. Biophys. Res. Comm. 90: 700–707, 1979CrossRefGoogle Scholar
  26. 26.
    Ulrich MMW, Furie, B, Jacobs, M, Vermeer, C, Furie BC: Vitamin K-dependent carboxylation: a synthetic peptide based upon the γ-carboxylation recognition site sequence of prothrombin propeptide is an active substrate for the carboxylase in vitro. J. Biol. Chem. 263: 9697–9702, 1988PubMedGoogle Scholar
  27. 27.
    Hubbard BR, Jacobs M, Ulrich MMW, Walsh C, Furie B, Furie BC: Vitamin K-dependent carboxylation: in vitro modification of synthetic peptides containing the γ-carboxylation recognition site. J. Biol. Chem. 264: 14145–14150, 1989PubMedGoogle Scholar
  28. 28.
    Bentley AK, Rees DJG, Rizza C, Brownlee GG: Defective propeptide processing of blood clotting Factor IX caused by mutation of arginine to glutamine at position-4. Cell 45: 343–348, 1986PubMedCrossRefGoogle Scholar
  29. 29.
    Sugimoto M, Miyata T, Kawabata S, Yoshioka A, Fukui G, Iwananga S: Factor IX Kawachinagano: impaired function of the Gla-domain caused by attached propeptide region due to substitution of arginine by glutamine at position-4. British J of Haematology 72: 216–221, 1989CrossRefGoogle Scholar
  30. 30.
    Galeffi P, Brownlee GG: The propeptide region of clotting factor IX is a signal for a vitamin K dependent carboxylase: evidence from protein engineering of amino acid — 4. Nucleic Acid Research 15: 9505–9513, 1987CrossRefGoogle Scholar
  31. 31.
    Price PA: Bone Gla protein and matrix Gla protein: Identification of the probable structures involved in substrate recognition by the γ-carboxylase and discovery of tissue differences in vitamin K metabolism, in Suttie J (ed): Current Advances in Vitamin K Research, New York, New York, Elsevier, 1988Google Scholar
  32. 32.
    Hubbard BR, Ulrich MMW, Jacobs M, Vermeer C, Walsh C, Furie B, and Furie BC: Vitamin K-dependent carboxylase: Affinity purification from bovine liver by using a synthetic propeptide containing the γ-carboxylation recognition site. Proc. Natl. Acad. Sci. USA 86: 6893–6897, 1989PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Barbara C. Furie
    • 1
    • 2
  • Bruce Furie
    • 1
    • 2
  1. 1.Division of Hematology/OncologyCenter for Hemostasis and Thrombosis ResearchBostonUSA
  2. 2.Departments of Medicine and BiochemistryTufts University School of MedicineBostonUSA

Personalised recommendations